United Therapeutics Corporation (UTHR) Stock Forecast
Data as of Sep 16, 2026Healthcare · Current price $504.20 (+0.73%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Apr 10, 2026 | Terence Flynn | Morgan Stanley | $519.00 | +2.9% |
| Mar 12, 2026 | Olivia Brayer | Cantor Fitzgerald | $625.00 | +24.0% |
| Feb 26, 2026 | Andrew Fein | H.C. Wainwright | $600.00 | +19.0% |
| Nov 19, 2025 | Eun Yang | Jefferies | $575.00 | +14.0% |
| Oct 30, 2025 | Andrew Fein | H.C. Wainwright | $525.00 | +4.1% |
| Oct 30, 2025 | Lisa Walter | RBC Capital | $587.00 | +16.4% |
| Oct 29, 2025 | Terrance Flynn | Morgan Stanley | $447.00 | -11.3% |
| Oct 10, 2025 | Terence Flynn | Morgan Stanley | $435.00 | -13.7% |
| Sep 10, 2025 | Olivia Brayer | Cantor Fitzgerald | $525.00 | +4.1% |
| Sep 5, 2025 | Andrew Fein | H.C. Wainwright | $500.00 | -0.8% |
| Sep 2, 2025 | Roger Song | Jefferies | $564.00 | +11.9% |
| Jul 31, 2025 | Andrew Fein | H.C. Wainwright | $400.00 | -20.7% |
| Apr 25, 2025 | Tiago Fauth | Wells Fargo | $314.00 | -37.7% |
| Oct 31, 2024 | Jasper Hellweg | Argus Research | $400.00 | -20.7% |
| Oct 31, 2024 | Andrew Fein | H.C. Wainwright | $425.00 | -15.7% |
| Sep 23, 2024 | Eun Yang | Jefferies | $432.00 | -14.3% |
| Aug 28, 2024 | Hartaj Singh | Oppenheimer | $575.00 | +14.0% |
| Jul 8, 2024 | Ashwani Verma | UBS | $370.00 | -26.6% |
| Jun 12, 2024 | Tiago Fauth | Wells Fargo | $350.00 | -30.6% |
| May 2, 2024 | Hartaj Singh | Oppenheimer | $400.00 | -20.7% |
Top Analysts Covering UTHR
UTHR vs Sector & Market
| Metric | UTHR | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.42 | 2.25 | 2.42 |
| Analyst Count | 12 | 8 | 18 |
| Target Upside | +29.3% | +16187.2% | +19.5% |
| P/E Ratio | 17.96 | 3.77 | 38.67 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-09-30 | $789M | $830M | $871M | 4 |
| 2026-12-31 | $820M | $863M | $906M | 8 |
| 2027-03-31 | $731M | $769M | $807M | 4 |
| 2027-06-30 | $739M | $778M | $816M | 4 |
| 2027-09-30 | $806M | $847M | $889M | 5 |
| 2027-12-31 | $958M | $1.01B | $1.06B | 4 |
| 2028-12-31 | $4.37B | $4.37B | $4.37B | 11 |
| 2029-12-31 | $4.78B | $5.27B | $5.81B | 5 |
| 2030-12-31 | $5.64B | $6.21B | $6.86B | 5 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-09-30 | $6.86 | $7.33 | $7.80 | 4 |
| 2026-12-31 | $7.23 | $7.72 | $8.22 | 4 |
| 2027-03-31 | $6.80 | $7.26 | $7.73 | 4 |
| 2027-06-30 | $6.83 | $7.30 | $7.77 | 4 |
| 2027-09-30 | $7.72 | $8.25 | $8.78 | 4 |
| 2027-12-31 | $9.67 | $10.33 | $11.00 | 4 |
| 2028-12-31 | $28.65 | $39.54 | $50.61 | 11 |
| 2029-12-31 | $41.93 | $47.60 | $54.01 | 4 |
| 2030-12-31 | $48.08 | $54.58 | $61.92 | 4 |
Frequently Asked Questions
What is the analyst consensus for UTHR?
The consensus among 12 analysts covering United Therapeutics Corporation (UTHR) is Buy with an average price target of $636.83.
What is the highest price target for UTHR?
The highest price target for UTHR is $625.00, set by Olivia Brayer at Cantor Fitzgerald on 2026-03-12.
What is the lowest price target for UTHR?
The lowest price target for UTHR is $205.00, set by Tiago Fauth at Credit Suisse on 2021-05-05.
How many analysts cover UTHR?
12 analysts have issued ratings for United Therapeutics Corporation in the past 12 months.
Is UTHR a buy or sell right now?
Based on 12 analyst ratings, UTHR has a consensus rating of Buy (2.42/5) with a +29.3% upside to the consensus target of $636.83.
What are the earnings estimates for UTHR?
Analysts estimate UTHR will report EPS of $7.33 for the period ending 2026-09-30, with revenue estimated at $830M.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.